Yeah, that's the mystery. Who is keeping things afloat and why? And if it's a real outside investor or investor group (vs. continuous insider injection of personal capital), what do they see that, apparently, nobody else sees? They clearly had some plan for what has happened financially, else they would not have restructured with new hires and an unsustainable burn rate a couple years ago. As I've been saying over and over, this is why I am so disappointed in the CEOs who have succeeded Dr. Musick. Zamora was clearly just manipulating the situation (at least as I see it as an outsider, extrapolating from info they have put in filings) -- so, in retrospect, his near total silence is explainable. But I expected more of Furman. To be fair, he immediately put the company on a fast track to renewed legitimacy with the SEC (and, presumably also helped out with the FDA, although I think that was Mosessian's primary gig). And to be more fair, their SEC filings have been comprehensive. But what we haven't seen at all is any kind of personal media or communication that lays out basic strategy. That's part of a CEO's job, along with manufacturing a public image. Back in the day, Dr. Musick would put together a complete summary every quarter or at least a couple times a year, which I appreciated. But, like Zamora, Furman has done none of that. Actually, he has done less, since Zamora actually did do a couple brief interviews early on before going silent. Again, I don't want to minimize the effort that went into reorganizing and getting to the precipice of being a legit biotech startup. But a few basic questions remain unanswered, and I think it's time to let the legacy shareholders know what is going on and when these clinical trials will begin.